What are monoclonal antibodies?
Monoclonal antibodies (mAbs) are man-made proteins that mimic the natural antibodies produced by our immune systems. Monoclonal antibodies can be formulated into medicines to treat various types of illnesses, such as certain cancers, rheumatoid arthritis or plaque psoriasis.
These advanced treatments are useful in treating cancer. Some monoclonal antibodies are targeted treatments and attack a very specific protein (antigens) on cancer cells. Others are considered immunotherapy because they help to boost our own immune system to find and attack cancers.
What are antibodies and antigens?
We have natural antibodies in our body. Antibodies are part of our immune system and seek out foreign substances (called antigens). Antibodies respond to antigens like viruses, bacteria, cancer cell proteins or other pathogens to mount an immune response and help kill them.
- For example, our natural antibodies seek out germs (certain viruses) to kill if we have a cold or flu. Other antibodies look for antigens (proteins) on the surface of cancer cells.
- Like our natural antibodies, man-made monoclonal antibodies work similarly to help our bodies destroy substances (antigens) that can allow diseases like cancer to grow.
"Monoclonal" means that the antibody recognizes one specific antigen (protein) in the body. Some antibodies, called "polyclonal" antibodies, come from several different immune cells and recognize more than one type of antigen.
How do monoclonal antibodies work in cancer?
Monoclonal antibodies work in different ways in cancer treatment. Not all cancer cells are the same, and researchers have utilized these differences to enable specific treatments that act on those differences.
Monoclonal antibodies work by:
- Helping to identify cancer cells to be destroyed by the immune system
- Triggering an immune response to help destroy cancer cells
- Blocking cancer cell growth
- Cutting off the blood vessel growth that feeds a tumor
- Boosting the effectiveness of the immune system to kill cancer cells
- Directly attacking cancer cells
- Acting as a transport system for treatments such as radiation or chemotherapy to deliver treatment directly to the cancer cells
- Using two monoclonal antibodies to help the immune system cells identify and attach to cancer cells (bispecific products)
For example, targeted therapy works by interacting with specific targets (instead of affecting all cells) found in cancer. Immunotherapy treatments help to boost our own immune system to work better against cancers found in the body. Immune checkpoint inhibitors, like Keytruda (pembrolizumab) or Opdivo (nivolumab) are examples of this type of mAb.
Monoclonal antibody-based treatments are now considered a standard part of cancer therapy when needed, alongside other options, such as surgery, chemotherapy, hormone treatment or radiation therapy.
What types of monoclonal antibodies are there?
Monoclonal antibodies (mAbs) may be classified as either Naked, Conjugated or as Bispecific. They are usually made in the lab from mouse proteins, human proteins or a combination of the two.
Naked mAbs: The types of treatments are usually given alone and usually attach to antigens on cancer cells, but may attach to healthy cells or other proteins. They have no other components, like radioactive materials or medicines, attached to them.
- These are the most common type of monoclonal antibody used clinically.
- One example of naked mAb is Herceptin (trastuzumab) which targets the HER2 protein in breast or stomach cancers. HER2 can help cancer cells to grow
Conjugated mAbs: These agents are combined with other drugs like chemotherapy (antibody-drug conjugates) or radioactive treatments. These tagged or labeled mABs help direct the treatment specifically to the cancer cells.
- One example is Zevalin (ibritumomab tiuxetan), a radioimmunotherapy. It binds specifically to the CD20 antigen which is found on white blood cells called B cells. It is used to treat non-Hodgkin's lymphoma (NHL). The mAb (ibritumomab) delivers a radioactive substance (Yttrium-90) directly to cancer cells.
- Another example is Kadcyla, an mAb that is attached to a chemotherapy drug. It targets the HER2 protein and is used to treat HER2-positive, metastatic breast cancer.
Bispecific mAbs: These medicines contain 2 mAbs which allow them to attach to 2 different proteins at the same time. These may also be called T-cell engagers (TCEs).
- One example is Lunsumio (mosunetuzumab-axgb, used to relapsed or refractory (R/R) follicular lymphoma, a type of blood cancer that affects white blood cells. Lunsumio is considered a Bispecific T-cell engagers (BiTE).
- It targets the CD20 antigen on the surface of B cells (cancerous white blood cells) and CD3 on the surface of T cells (a white blood cell that helps to protect you from disease.). The mAb redirects the existing T cells to target B cells by releasing cytotoxic proteins into the B cells to kill the cancer.
Classification of Monoclonal Antibodies
- Anti-CTLA-4 monoclonal antibodies
- Anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
- Antiviral monoclonal antibodies
- CD19 monoclonal antibodies
- CD20 monoclonal antibodies
- CD30 monoclonal antibodies
- CD33 monoclonal antibodies
- CD38 monoclonal antibodies
- CD52 monoclonal antibodies
What diseases do monoclonal antibodies treat?
Some of the diseases that can be treated with monoclonal antibodies include:
- Cancer like blood cancers and solid tumors
- Inflammatory bowel disease, like Crohn’s disease or ulcerative colitis
- Severe allergies
- Autoimmune disorders
- Infections
- Osteoporosis
- Severe asthma
- Eye conditions, like thyroid eye disease (TED)
- Migraine headaches
- High cholesterol
- Alzheimer’s disease
Active research is ongoing to develop new medicines and find new uses for monoclonal antibodies. You may be eligible to join a clinical trial for treatment. Speak to your doctor about this option.
What are some examples of monoclonal antibodies?
Orthoclone OKT3 (muromonab-CD3) was the first licensed monoclonal antibody in the U.S. It gained clearance from the FDA in 1986 for use in preventing kidney transplant rejection. New monoclonal antibodies are constantly under research.
List of monoclonal antibodies and diseases they treat:
- Aduhelm (aducanumab) - Alzheimer's disease
- Avastin (bevacizumab) - brain tumors, and cancers of the kidney, liver, lung, colon, rectum, cervix, ovary, or Fallopian tube
- Blincyto (blinatumomab) - Acute lymphoblastic leukemia
- Cosentyx (secukinumab) - plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, enthesitis-related arthritis, and non-radiographic axial spondyloarthritis
- Fasenra (benralizumab) - severe asthma
- Humira (adalimumab) - rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, Crohn's disease, and ulcerative colitis (among others).
- Herceptin (trastuzumab) - breast cancer, advanced gastric (stomach) cancer
- Kesimpta (ofatumumab) - relapsing multiple sclerosis (MS)
- Keytruda (pembrolizumab) - liver, skin (melanoma), lung, breast or esophageal cancer (among others)
- Ocrevus (ocrelizumab) - multiple sclerosis
- Opdivo (nivolumab) - melanoma (advanced skin cancer), non-small cell lung cancer, renal cell (kidney) cancer, bladder cancer (among others)
- Remicade (infliximab) - rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, ulcerative colitis and Crohn's disease
- Rituxan (rituximab) - non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis (among others)
- Skyrizi (risankizumab) - plaque psoriasis, psoriatic arthritis, Crohn’s disease
- Takhzyro (lanadelumab-flyo) - prevention of attacks of hereditary angioedema (HAE)
- Taltz (ixekizumab) - plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis
- Tepezza (teprotumumab) - thyroid eye disease (TED or Graves Eye Disease)
- Tremfya (guselkumab) - plaque psoriasis, psoriatic arthritis
- Xolair (omalizumab) - allergic asthma, nasal polyps and chronic hives (chronic spontaneous urticaria).
Related questions
- What are biosimilar drugs and how do they compare to biologics?
- What is TCHP chemotherapy and how is it used?
- How soon can you start chemo after port placement?
More recent monoclonal antibodies approved by the FDA include:
- Columvi (glofitamab) - diffuse large B-cell lymphoma
- Elahere (mirvetuximab soravtansine-gynx) - ovarian cancer
- Epkinly (epcoritamab-bysp) - diffuse large B-cell lymphoma (DLBCL)
- Leqembi (lecanemab-irmb) - Alzheimer’s disease
- Loqtorzi (toripalimab) - advanced nasopharyngeal carcinoma (NPC), a rare type of cancer of the nose or throat
- Lunsumio (mosunetuzumab-axgb_- follicular lymphoma
- Zynyz (retifanlimab-dlwr) - Merkel cell carcinoma (an aggressive type of skin cancer)
Learn more: What is the mechanism of action (MOA) of Loqtorzi (toripalimab)?
*Note: This is not a complete list of all monoclonal antibodies available on the U.S. market or their indications. New drugs and uses are frequently approved by the FDA. If you have further questions about monoclonal antibodies you can search by name here and contact your healthcare provider.
How are monoclonal antibodies given?
These medicines are often injected into a vein (intravenously). You may receive this treatment at a special clinic called an infusion center. Your doctor will monitor you for any infusion or allergic reactions before you go home.
In some cases, monoclonal antibodies are injected subcutaneously (just under the skin) instead of into a vein.
Different drugs will have different schedules for administration based on your cancer type. Not all cancer regimens include monoclonal antibodies as part of the treatment plan.
Are biosimilars approved for monoclonal antibodies?
Biosimilars are increasingly being approved for many biologics, including monoclonal antibodies.
- A biosimilar is a biological product that is similar to the reference product (usually the original brand name product).
- Biosimilars have no clinically meaningful differences in terms of safety, purity, and potency.
- Unlike most chemically-derived small-molecule drugs, biological products are generally derived from a living organism, such as microorganisms or yeast.
A biosimilar is not considered a “generic” in the same way that a traditional, small molecule drug (for example: ibuprofen or acetaminophen) is classified as a generic. As with generics, biosimilar cost savings for healthcare systems and the consumer are expected to be significant.
One example is Amjevita (adalimumab-atto), a tumor necrosis factor blocker and the first biosimilar approved for Humira. It is used for most of the same indications as Humira, including rheumatoid arthritis, Crohn's disease and psoriasis, but is not approved for uveitis. In this case, Humira is the reference product.
Learn more: What biosimilars have been approved in the United States?
What side effects occur with monoclonal antibodies?
A wide range of side effects can occur with monoclonal antibodies, depending upon your drug treatment and use. Some side effects can be very rare but can be serious or life-threatening, while other side effects may be common but not serious.
Talk with your healthcare provider about which side effects to expect from your treatment.
Common side effects
In general, common side effects with monoclonal antibodies can include:
- Allergic reactions, such as hives or itching
- Flu-like symptoms (chills, extreme tiredness, fever, and muscle aches and pains)
- Nausea and vomiting
- Diarrhea
- Skin rashes
- Low blood pressure
Infusion reactions, which are more common when the drug is first being started, can include low blood pressure, fever, chills, skin rash, weakness, nausea/vomiting, headache, or diarrhea. Your doctor may give you medicine before your treatment to help prevent this side effect. Your cancer care team will watch you closely for this side effect.
Serious side effects
Serious, but less common, side effects may include:
- Serious infusion reactions, which can be a life-threatening allergic reaction.
- Heart problems like a risk for high blood pressure, congestive heart failure and heart attacks.
- Lung inflammation or other lung problems.
- Skin problems, like sores and rashes or sores on the tissue that lines your cheeks and gums (mucosa).
- Increased risk of serious bleeding, like internal bleeding.
To learn more about clinical trials through the National Cancer Institute, visit here.
This is not all the information you need to know about Monoclonal Antibodies for safe and effective use and does not take the place of your doctor’s directions. Review the full product information you receive about your medicine. Discuss this information and any questions you have with your doctor or other health care provider.
References
- Immunotherapy. American Cancer Society. Accessed June 3, 2025 at https://www.cancer.org/content/dam/CRC/PDF/Public/6678.00.pdf
- Monoclonal antibodies. Cancer Research UK. Accessed June 3, 2025 at https://www.cancerresearchuk.org/about-cancer/treatment/immunotherapy/types/monoclonal-antibodies
- National Cancer Institute (NCI). Find NCI-Supported Clinical Trial. Accessed June 3, 2025 at https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/advanced
- Monoclonal antibodies. Cleveland Clinic. Accessed June 3, 2025 at https://my.clevelandclinic.org/health/treatments/22246-monoclonal-antibodies
- Monoclonal Antibodies and Their Side Effects. American Cancer Society. Accessed June 3, 2025 at https://www.cancer.org/cancer/managing-cancer/treatment-types/immunotherapy/monoclonal-antibodies.html
- Manis J. Overview of therapeutic monoclonal antibodies. Up to Date. Accessed June 21, 2023 at https://www.uptodate.com/contents/overview-of-therapeutic-monoclonal-antibodies#H2824611726
Read next
How long can you stay on Herceptin and Perjeta?
If you are receiving Perjeta for treatment of HER2+ early breast cancer, you may continue treatments with Herceptin every 3 weeks for one year (18 cycles total). For the treatment of HER2+ metastatic breast cancer, you will receive Perjeta and Herceptin until the medicine no longer controls your breast cancer or you have side effects that require you to stop treatment. You may receive other treatments with these medications. Continue reading
What happens after Herceptin treatment?
After Herceptin treatment, your doctor will monitor you regularly for cancer progression, advise you not to become pregnant for at least 7 months (if you are of childbearing potential), and test your heart every 6 months for at least 2 years, because there is a higher risk of developing long-term heart damage in people who take Herceptin. Continue reading
How long can I stay on Herceptin?
Treatment regimens for Herceptin vary depending on hospital protocols, but for the treatment of HER2+ early breast cancer, treatment is usually continued for one year (up to 18 cycles). Continue reading
See also:
Aimovig
Learn about Aimovig (erenumab-aooe) a once-monthly, injectable medication that can be ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Stelara
Stelara (ustekinumab) is used to treat Crohn's disease, ulcerative colitis, plaque psoriasis, and ...
Nurtec ODT
Nurtec ODT (rimegepant) is used to treat acute migraines and prevent episodic migraines, by ...
Vyepti
Vyepti (eptinezumab-jjmr) is used for the preventive treatment of migraine. Includes Vyepti ...
Depakote
Depakote is used to treat various types of seizure disorders. Learn about side effects ...
Topamax
Topamax (topiramate) is used to prevent seizures in adults and children and to prevent migraine ...
Emgality
Emgality (galcanezumab-gnlm) is a CGRP antagonist for the preventive treatment of migraine and for ...
Inderal
Inderal (propranolol) is used to treat angina, high blood pressure and heart rhythm disorders ...
Related medical questions
- What are the biosimilars of Herceptin?
- What are biologic drugs and how do they work?
- What biosimilars have been approved in the United States?
- What is Herceptin? Is Herceptin a chemo drug? How does it work?
- How long does Herceptin stay in your body?
- How do Herceptin (trastuzumab) and Perjeta (pertuzumab) work together?
- How effective is Herceptin for Breast & Gastric Cancer?
- What is the difference between Herceptin and Herceptin Hylecta?
- Does Herceptin (trastuzumab) stop menstrual periods?
- Do Herceptin (trastuzumab) injections hurt?
- What is the difference between Herzuma and Herceptin?
- What is the difference between Ogivri and Herceptin?
- How is Herceptin Injection and Herceptin Hylecta administered?
- Who is the actress in the Skyrizi commercial?
- What's the dosing schedule for Skyrizi?
- Does Skyrizi cause cancer?
- Can you drink alcohol while taking Skyrizi?
- Skyrizi vs Humira for plaque psoriasis - How do they compare?
- Who makes Skyrizi and where is it made?
- Does Skyrizi cause hair loss?
- Is Skyrizi approved for treating psoriatic arthritis?
- Skyrizi vs Ilumya. What’s the difference?
- What are the new drugs for plaque psoriasis?
- How long does it take for Skyrizi to work?
- What causes Plaque Psoriasis?
- Who sings the Skyrizi song ‘Nothing is everything’?
- How does Skyrizi work (MOA)?
- How is Skyrizi injection administered?
Related support groups
- Herceptin (21 questions, 32 members)
- Skyrizi (18 questions, 9 members)
- Loqtorzi (1 questions, 3 members)
- Humira (69 questions, 370 members)
- Xolair (25 questions, 89 members)
- Remicade (23 questions, 186 members)
- Rituxan (21 questions, 105 members)
- Cosentyx (20 questions, 25 members)
- Keytruda (19 questions, 63 members)
- Opdivo (18 questions, 53 members)
- Ocrevus (15 questions, 16 members)